{"id":"W3163488215","doi":"10.1136/rmdopen-2021-001679","title":"Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials","year":2021,"lang":"en","type":"article","venue":"RMD Open","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Infection and Immunity","funders":"Janssen Research and Development; Celgene; Biogen; Gilead Sciences; Asia Pacific League of Associations for Rheumatology; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Ustekinumab; Arthritis; Immunology; Interleukin 23; Interleukin 17; Secukinumab; Internal medicine; C-reactive protein; Psoriasis; Placebo; Acute-phase protein; Cytokine; Tumor necrosis factor alpha; Gastroenterology; Inflammation; Adalimumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004529216,0.0002116201,0.000934116,0.000120282,0.00008430824,0.00009150658,0.00008344887,0.0001146968,0.0001447396],"category_scores_gemma":[0.00124516,0.000182556,0.00005348268,0.0004329317,0.0000429558,0.0002947245,0.0001427926,0.0001913224,0.00001829371],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001365857,"about_ca_system_score_gemma":0.0001773688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002337019,"about_ca_topic_score_gemma":0.002230476,"domain_scores_codex":[0.9981611,0.0002921568,0.000584873,0.0005384503,0.0001780606,0.0002453581],"domain_scores_gemma":[0.9991221,0.0002072997,0.0001912037,0.0002840355,0.00009977859,0.00009560338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.07846819,0.009989793,0.0009416176,0.0001040824,0.002224681,0.007723104,0.008305034,0.00001149393,0.1480649,0.00003083303,0.003511769,0.7406245],"study_design_scores_gemma":[0.6400318,0.008040529,0.03916364,0.005639062,0.001046596,0.0003695498,0.004546829,0.00008676483,0.2931522,0.0005833596,0.006484012,0.000855646],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912872,0.003553945,0.000001899978,0.0009499741,0.0003688027,0.00260078,0.0007190885,0.00002000866,0.0004983511],"genre_scores_gemma":[0.993833,0.003465038,0.0008462396,0.000057335,0.0002590638,0.0003526043,0.0008479079,0.00002436216,0.0003144214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7397689,"threshold_uncertainty_score":0.7444417,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07613190494484223,"score_gpt":0.3808470611294208,"score_spread":0.3047151561845786,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}